featured
-
July 2026: This Month in Huntington’s Disease Research
ā±ļø 8 min read | July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and important work on eating and self-awareness in HD.
-
Putting it in print: a clinical trial trying to rein in runaway pruning
ā±ļø10 min read | Four years after announcing positive results in their trial of ANX005 (tanruprubart) for HD, Annexon has formally published the results. Itās safe, hits its target, and may have helped some participants ā so whatās the holdup?
By Dr Leora Fox -
Joining the Starting Lineup: MutLĪ²ās Role in DNA Repeat Expansions
ā±ļø8 min read | Scientists have known that MutLĪ² is linked to repeat expansion but not exactly how. A study reveals that the MutLĪ² protein complex is a main player supporting and interacting with key DNA repair proteins to drive DNA repeat expansions.
-
Catching a Giant Protein: Five New Ways to Grab Huntingtin
ā±ļø8 min read | Scientists screened over a trillion tiny ring-shaped protein fragments to find ones that can grab onto the huntingtin. They captured huntingtin straight out of cells and discovered itās almost always paired with a partner called HAP40.
-
Mirror, Mirror on the Wall: When Self-Awareness Shifts in Huntingtonās Disease
ā±ļø6 min read | A new study suggests that reduced awareness of symptoms, known as anosognosia, may appear even in the earliest stages of HD. The findings highlight that understanding symptom progression requires more than one perspective.
-
More Than Just Food: The Hidden Challenges of Eating with Huntingtonās Disease
ā±ļø8 min read | People with Huntingtonās disease commonly experience unintended weight loss. A recent article identified the challenges around HDās impact on eating and weight maintenance, and explored how families and professionals navigate them.
-
Roche ends two Huntington’s disease drug programmes after disappointing results
ā±ļø 10 min read | Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research.Ā
-
Are we finally getting that PET weāve always wanted?
ā±ļø8 min read | For the past 20 years, PET tracers have been a game-changer for Alzheimerās disease, making it possible to see amyloid plaques in the brain without invasive procedures. So what about Huntington’s?
-
Skyhawk Shares A Closer Look at SKY-0515 Data, Plus A Peek At Expanding US Trial Access
ā±ļø 6 min read | New 12-month data from Skyhawk’s SKY-0515 is in and all four measures that make up the cUHDRS are at or above baseline, beating expected natural decline. Plus, a first look at expanding US trial sites.
-
June 2026: This Month in Huntington’s Disease Research
ā±ļø 10 min read | From the clinic, we heard from uniQure about their recent FDA meeting, a stem cell trial dosed its first participant, and Skyhawk shared data on SKY-0515. In the lab, the science of slowing HD at the DNA level keeps building.